A small calorie surplus each day compounds into serious weight problems by middle age.
After fifteen years of scientific development and six years of regulatory scrutiny, European authorities have granted formal approval to inulin propionate ester, a fiber-based food additive designed to curb appetite and prevent gradual weight gain. Born in university laboratories rather than pharmaceutical boardrooms, IPE represents a quieter kind of intervention — one that works with the body's own hormonal signals rather than overriding them. Its approval marks a rare moment when academic patience and public health ambition converge into something that might one day sit, unnoticed, in an ordinary bowl of cereal.
- Obesity accumulates slowly and invisibly — even a single kilogram of annual weight gain in young adulthood is enough to alter a person's health trajectory for decades.
- Most people fall far short of recommended fiber intake, and telling them to eat more vegetables has proven an ineffective public health strategy at scale.
- IPE delivers propionate directly to appetite-regulating receptors in the colon, amplifying the body's natural fullness signals without drugs, surgery, or dietary overhaul.
- The spinout company Satisfed is now racing to find industrial partners who can scale production from hundreds of kilograms to thousands of tonnes.
- Developers are targeting underserved communities where cost and food access drive disproportionate rates of obesity, positioning IPE as a preventive tool before pharmaceutical intervention becomes necessary.
After fifteen years in the laboratory, a white powder developed by scientists at Imperial College London and the University of Glasgow has cleared one of Europe's most rigorous regulatory hurdles. Inulin propionate ester — IPE — now appears on the EU's official list of approved novel foods, a designation that signals the European Food Safety Authority has found it safe for human consumption. It is not a drug or a surgery, but a fiber-based ingredient that can be stirred into smoothies, baked into bread, or sprinkled over cereal.
The molecule combines inulin, a natural substance found in chicory and onions, with propionate, a short-chain fatty acid the body already produces. When consumed, IPE travels to the colon and triggers the release of appetite-regulating hormones, amplifying the natural fullness that high-fiber foods provide. Randomized controlled trials showed that roughly ten grams per day can meaningfully regulate appetite and prevent gradual weight gain from compounding over time.
Professor Gary Frost frames the problem in terms of arithmetic: a small, unnoticed daily calorie surplus is enough to reshape a person's health by middle age. Douglas Morrison, who first synthesized the molecule at the University of Glasgow, spent fifteen years running clinical studies alongside Frost and publishing results in peer-reviewed journals. Longer-term trials hinted at additional benefits — preserved lean muscle mass, reduced liver fat, and metabolic improvements. The European Food Safety Authority then spent six years reviewing the evidence before issuing a positive opinion in late 2025, with the European Commission granting final authorization shortly after.
What makes this approval unusual is that it happened without a major pharmaceutical company behind it. Morrison and Frost pursued a direct bench-to-consumer pathway, demonstrating that university-based discoveries need not languish in academic literature. Yet approval is not the same as availability. The team can currently produce only a few hundred kilograms at a time, and their spinout company, Satisfed, is now seeking industrial partners capable of scaling to thousands of tonnes. The developers see IPE as a low-cost preventive tool — one that could reach communities where food access and affordability already shape unequal patterns of obesity, offering a quiet intervention before the problem grows serious enough to require pharmaceutical treatment.
After fifteen years in the laboratory, a white powder developed by scientists at Imperial College London and the University of Glasgow has cleared one of Europe's most rigorous regulatory hurdles. Inulin propionate ester—IPE for short—now appears on the EU's official list of approved novel foods, a designation that signals the European Food Safety Authority has found it safe for human consumption. The additive represents a different kind of answer to weight gain: not a drug, not a surgery, but a fiber-based ingredient that can be stirred into smoothies, baked into bread, or sprinkled over cereal.
The molecule itself is elegantly simple. It combines inulin, a natural substance found in chicory and onions, with propionate, a short-chain fatty acid that occurs naturally in the body. When consumed, IPE travels through the digestive system and delivers propionate directly to receptors in the colon, triggering the release of hormones that regulate appetite. The effect is to amplify what happens naturally when people eat high-fiber foods—the feeling of fullness that makes it easier to eat less. Randomized controlled trials showed that roughly ten grams per day can meaningfully regulate appetite and prevent weight gain from accumulating over time.
Professor Gary Frost, who chairs nutrition and dietetics at Imperial College, frames the problem IPE is meant to solve in terms of arithmetic. A small calorie surplus each day—the kind most people don't consciously notice—compounds into serious weight problems by middle age. Even one kilogram of weight gain per year in young adulthood is enough to reshape a person's health trajectory. Most people fall short of recommended fiber intake, and simply eating more vegetables is not a realistic intervention at scale. IPE offers a way to deliver the appetite-suppressing benefits of fiber without requiring people to overhaul their diets.
The path to approval took longer than the science itself. Douglas Morrison, a researcher at SUERC at the University of Glasgow, first developed the molecule in the lab. He then spent the next fifteen years collaborating with Frost, running clinical studies, and publishing results in peer-reviewed journals. Some of the longer-term trials hinted at additional benefits: preservation of lean muscle mass, improvements in liver fat levels, and potential effects on immune and metabolic health. But the real test came when the researchers submitted their data to the European Food Safety Authority, which scrutinizes toxicological, nutritional, and microbiological evidence. That review alone consumed six years. In late 2025, the authority issued a positive opinion. The European Commission granted final authorization, and IPE was formally added to the list.
What makes this approval noteworthy is that it happened without the backing of a major pharmaceutical company. Morrison and Frost pursued what they call a "bench-to-consumer" pathway—moving an academic innovation directly toward the market. It required patience and persistence, but it proved possible. The researchers note that their success demonstrates a route for university-based discoveries that might otherwise languish in the literature.
Yet approval is not the same as availability. The research team can currently manufacture IPE only at pilot scale, producing a few hundred kilograms at a time. To reach consumers in meaningful quantities, they have launched a spinout company called Satisfed and are now hunting for industrial partners capable of scaling production to thousands of tonnes. Morrison and Frost describe IPE as cheap and effective—a dietary intervention that could be particularly valuable in communities where cost and access to healthy food contribute to uneven patterns of obesity. The developers hope to see IPE incorporated into mainstream foods, offering people who are beginning to struggle with their weight a preventive tool before the problem becomes entrenched enough to require pharmaceutical intervention like GLP-1 receptor agonists.
The commercial journey is just beginning. But for the first time, the regulatory pathway is clear, and the science is settled. What remains is the work of turning a laboratory discovery into something millions of people might eat without thinking about it—a fiber that works quietly in the background, making fullness easier to find.
Notable Quotes
A small calorie surplus each day will lead to significant weight gain over time. Even 1 kilogram a year in young adults is enough to create serious weight problems by middle age.— Professor Gary Frost, Imperial College London
IPE could help stop the kind of slow, steady weight gain that makes pharmaceutical interventions necessary.— Professor Douglas Morrison, University of Glasgow
The Hearth Conversation Another angle on the story
Why does this matter now, when we already know fiber helps with weight gain?
Because most people don't eat enough fiber, and telling them to eat more vegetables hasn't worked at scale. IPE lets you deliver the benefit without changing someone's entire diet.
So it's not a weight-loss drug. What's the difference?
It's preventive, not corrective. It stops the slow creep of weight gain before it becomes a problem that requires medication. A kilogram a year sounds small until you're forty and you've gained twenty.
How does it actually work in the body?
It travels to the colon and triggers the same appetite-regulating hormones your gut naturally produces when you eat fiber. But it delivers the signal more directly, more efficiently—it supercharges what already happens.
Fifteen years is a long time. What took so long?
Most of that was regulatory review. The science moved faster than the bureaucracy. Six years just for the European Food Safety Authority to evaluate the safety data.
Can you buy it now?
Not yet. They can only make it in small batches. They need industrial partners to scale up to the quantities that would actually reach grocery stores and bakeries.
Who benefits most from this?
People in communities where healthy food is expensive or hard to access. This is cheap to produce and can be added to foods people already eat.